Intech Biopharm Ltd (6461) AI Stock Analysis

Intech Biopharm Ltd

(TPEx:6461)

Select Model

Rating:42Neutral

Price Target:TWD 26.00▼(-2.07% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by severe losses, negative cash flow, and weak valuation. Mixed but generally neutral technical indicators provide limited support, resulting in a low overall stock score.

Positive Factors

Improved LeverageDebt-to-equity fell from about 1.76 to 1.08 in 2025, indicating a meaningful improvement in leverage relative to the prior year. This gives the company a stronger balance-sheet position than before and could reduce financial strain, although debt remains substantial.

Negative Factors

Structural UnprofitabilityPersistent net losses and deeply negative gross margins show that the business is not currently converting revenue into economic value. The 2025 gross margin near -112% indicates severe cost intensity, limiting the likelihood that additional sales alone will quickly produce sustainable profitability.

Intech Biopharm Ltd (6461) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 2.87B
Dividend Yield: ―
Average Volume (3M): 110.65K
Price to Earnings (P/E): -5.9
Beta (1Y): 0.66
Revenue Growth: -57.87%
EPS Growth: -21.67%
Country: TW
Employees: 96
Sector: General
Sector Strength: 55
Industry: Biotechnology

Intech Biopharm Ltd Business Overview & Revenue Model

Company Description

Intech Biopharm Corporation is a pharmaceutical company dedicated to the global development and production of generic medications for respiratory conditions. Their portfolio includes innovative drug delivery systems, such as iLEF (inhaled low ethanol...

Intech Biopharm Ltd Financial Statement Overview

Summary

Very weak financial performance: severe net losses, deeply negative margins, negative operating and free cash flow, and ongoing value destruction. Lower debt and improved equity provide limited support, but financial risk remains substantial.

Income Statement

8Very Negative

Balance Sheet

35Negative

Cash Flow

12Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	48.55M	107.53M	39.78M	25.85M	23.65M	38.90M
Gross Profit	-192.27M	-120.12M	-157.63M	-164.00M	-147.26M	-119.37M
EBITDA	-368.73M	-273.24M	-246.70M	-219.59M	-219.48M	-197.40M
Net Income	-482.02M	-389.03M	-368.21M	-337.99M	-327.88M	-301.76M
Balance Sheet
Total Assets	2.30B	2.35B	2.40B	2.71B	2.55B	2.60B
Cash, Cash Equivalents and Short-Term Investments	145.42M	214.30M	258.68M	598.13M	374.94M	335.48M
Total Debt	1.33B	1.19B	1.44B	1.44B	1.41B	1.15B
Total Liabilities	1.40B	1.25B	1.58B	1.54B	1.52B	1.26B
Stockholders Equity	894.40M	1.10B	814.28M	1.17B	1.03B	1.34B
Cash Flow
Free Cash Flow	-419.15M	-425.14M	-312.84M	-234.34M	-201.39M	-221.91M
Operating Cash Flow	-372.70M	-361.13M	-269.22M	-204.13M	-190.39M	-200.61M
Investing Cash Flow	152.97M	-197.48M	422.37M	-240.21M	-205.94M	-35.52M
Financing Cash Flow	19.47M	377.28M	-32.43M	485.20M	238.71M	251.92M

Intech Biopharm Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6461 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1752	65Neutral	TWD 3.02B	16.07	―	5.35%	-6.10%	-26.89%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6461	42Neutral	TWD 2.94B	-5.89	―	―	-57.87%	-21.67%
TW:3205	41Neutral	TWD 3.01B	-195.33	―	―	4.86%	83.87%
TW:6875	37Underperform	TWD 3.24B	-9.12	―	―	-69.26%	-24.53%

* General Sector Average

Performance Comparison

TW:6461 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6461	Intech Biopharm Ltd	26.55	1.66	6.65%
TW:1752	Nang Kuang Pharmaceutical Co., Ltd.	29.90	-6.84	-18.62%
TW:3205	Sagittarius Life Science Corp.	44.75	-2.40	-5.09%
TW:6838	Formosa Pharmaceuticals, Inc.	20.60	-6.85	-24.95%
TW:6875	Pharmosa Biopharm Inc.	25.05	-24.60	-49.55%
TW:7427	Great Novel Therapeutics Biotech & Medicals Corp.	59.50	21.41	56.22%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Intech Biopharm Ltd AI Stock Analysis